C. Doering

发表

Regulatory Framework for Academic Investigator-Sponsored Investigational New Drug Development of Cell and Gene Therapies in the USA

A. Dasgupta, Kristen Herzegh, H. Spencer, 2021, Current Stem Cell Reports.

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery

J. F. Wright, Shangzhen Zhou, H. Spencer, 2013, Molecular therapy. Methods & clinical development.

Engineered Hematopoietic Stem Cells as Therapeutics for Hemophilia A.

H. Spencer, C. Doering, P. Zakas, 2011, Journal of genetic syndromes & gene therapy.

Simplified prototyping of perfusable polystyrene microfluidics.

David R. Myers, D. R. Myers, C. Doering, 2014, Biomicrofluidics.

High-level protein production in erythroid cells derived from in vivo transduced hematopoietic stem cells.

Hongjie Wang, T. Papayannopoulou, A. Lieber, 2019, Blood advances.

Leucine toxicity in a neuronal cell model with inhibited branched chain amino acid catabolism.

A. Kasinski, C. Doering, D. Danner, 2004, Brain research. Molecular brain research.

Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A

A. Atala, A. Skardal, Julio Aleman, 2021, Frontiers in Bioengineering and Biotechnology.

Non-signaling Chimeric Antigen Receptors Enhance Antigen-Directed Killing by γδ T Cells in Contrast to αβ T Cells

S. Becker, H. Spencer, C. Doering, 2020, Molecular therapy oncolytics.

A1 Subunit-mediated Regulation of Thrombin-activated Factor VIII A2 Subunit Dissociation*

C. Doering, P. Lollar, E. Parker, 2006, Journal of Biological Chemistry.

Bortezomib enhances cytotoxicity of ex vivo expanded gamma delta (γδ) T cells against AML and T-ALL

C. Doering, J. Hamilton, Sunil S. Raikar, 2021 .

Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC.

E. Colletti, G. Almeida-Porada, C. Porada, 2011, Experimental hematology.

The Immune Response to the fVIII Gene Therapy in Preclinical Models

H. Spencer, C. Doering, K. Pratt, 2020, Frontiers in Immunology.

Human mutations affecting branched chain alpha-ketoacid dehydrogenase.

C. Doering, D. Danner, Christopher B. Doering, 1998, Frontiers in bioscience : a journal and virtual library.

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A

A. Atala, G. Almeida-Porada, C. Porada, 2020, Molecular therapy. Methods & clinical development.

Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway

W. H. Baldwin, S. Stowell, C. Doering, 2022, Frontiers in Immunology.

Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A

J. F. Wright, H. Spencer, C. Doering, 2016, Molecular therapy. Methods & clinical development.

Characterization of Donor Variability for γδ T Cell ex vivo Expansion and Development of an Allogeneic γδ T Cell Immunotherapy

G. Gibson, L. Bixby, H. Spencer, 2020, Frontiers in Medicine.

High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors.

C. Hausl, C. Doering, H. Schwarz, 2005, Blood.

High-throughput screening identifies compounds that enhance lentiviral transduction

H. Spencer, C. Doering, J. M. Johnston, 2014, Gene Therapy.

Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette

Arun Srivastava, G. Gao, R. Herzog, 2021, Molecular therapy. Methods & clinical development.

Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B.

R. Herzog, A. Srivastava, H. Spencer, 2020, Human gene therapy.

State of the art: gene therapy of haemophilia

H. Spencer, C. Doering, B. Riley, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Generation of an Optimized Lentiviral Vector Encoding a High-Expression Factor VIII Transgene for Gene Therapy of Hemophilia A

H. Spencer, C. Doering, J. M. Johnston, 2012, Gene Therapy.

Gene Therapy Strategies Incorporating Large Transgenes

H. Spencer, C. Doering, J. M. Johnston, 2011 .

Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein.

C. Kempton, C. Doering, S. Meeks, 2011, Blood.

Amino acid deprivation induces translation of branched-chain alpha-ketoacid dehydrogenase kinase.

C. Doering, D. Danner, 2000, American journal of physiology. Cell physiology.

Retroviral modification of mesenchymal stem cells for gene therapy of hemophilia.

C. Doering, 2008, Methods in molecular biology.

Amino acid deprivation induces translation of branched-chain α-ketoacid dehydrogenase kinase

C. Doering, D. Danner, 2000 .

Development and Characterization of Recombinant Ovine Coagulation Factor VIII

G. Almeida-Porada, C. Porada, H. Spencer, 2012, PloS one.

Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.

H. Spencer, C. Doering, B. Gangadharan, 2009, Human gene therapy.

Insulin increases branched-chain alpha-ketoacid dehydrogenase kinase expression in Clone 9 rat cells.

A. Kasinski, C. Doering, M. Nellis, 2002, American journal of physiology. Endocrinology and metabolism.

SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa

H. Spencer, C. Doering, P. Lollar, 2022, Blood advances.

Rapid generation of stable cell lines expressing high levels of erythropoietin, factor VIII, and an antihuman CD20 antibody using lentiviral vectors.

H. Zayed, H. Spencer, C. Doering, 2013, Human gene therapy methods.

Functional aspects of factor VIII expression after transplantation of genetically‐modified hematopoietic stem cells for hemophilia A

H. Spencer, C. Doering, B. Gangadharan, 2010, The journal of gene medicine.

Advancements in gene transfer-based therapy for hemophilia A

H. Spencer, C. Doering, 2009, Expert review of hematology.

The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain

H. Spencer, C. Doering, I. Smith, 2020, Journal of thrombosis and haemostasis : JTH.

hemophilia A with factor VIII inhibitors High-dose factor VIII inhibits factor VIII-specific memory B cells in

C. Hausl, C. Doering, H. Schwarz, 2012 .

hemophilia A with factor VIII inhibitors specific memory B cells in − High-dose factor VIII inhibits factor VIII

C. Hausl, C. Doering, H. Schwarz, 2005 .

Identification of Porcine Coagulation Factor VIII Domains Responsible for High Level Expression via Enhanced Secretion*

C. Doering, J. Healey, P. Lollar, 2004, Journal of Biological Chemistry.

High Level Expression of Recombinant Porcine Coagulation Factor VIII*

C. Doering, J. Healey, P. Lollar, 2002, The Journal of Biological Chemistry.

Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A.

H. Spencer, C. Doering, J. M. Johnston, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors

C. Doering, S. Meeks, P. Zakas, 2015, Journal of thrombosis and haemostasis : JTH.

B-Cell Epitopes Within The A2 and C2 Domains Of Coagulant Factor VIII Refined By Orthologous Protein Antigenicity

C. Doering, S. Meeks, P. Zakas, 2013 .

Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor

H. Spencer, C. Doering, P. Lollar, 2021, Frontiers in Immunology.

Structure of Blood Coagulation Factor VIII in Complex with Anti-C2 Domain Inhibitory Antibody

H. Spencer, C. Doering, P. Lollar, 2021 .

Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice

S. Stowell, H. Spencer, C. Doering, 2022, Blood Advances.

Potentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition

C. Doering, B. Gangadharan, S. Meeks, 2012, PLoS ONE.

Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.

H. Spencer, C. Doering, B. Gangadharan, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Enhanced Biosynthesis of Coagulation Factor VIII through Diminished Engagement of the Unfolded Protein Response*

C. Doering, B. Gangadharan, Harrison C. Brown, 2011, The Journal of Biological Chemistry.

High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells.

H. Spencer, C. Doering, B. Gangadharan, 2006, Blood.

Expression and Characterization of Recombinant Murine Factor VIII

C. Doering, J. Healey, P. Lollar, 2002, Thrombosis and Haemostasis.

Delivery of nucleic acid therapeutics by genetically engineered hematopoietic stem cells.

H. Spencer, C. Doering, D. Archer, 2010, Advanced drug delivery reviews.

Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.

Eli J. Fine, H. Spencer, C. Doering, 2018, Human gene therapy.

Replacing bad (F)actors: hemophilia.

H. Spencer, C. Doering, 2014, Hematology. American Society of Hematology. Education Program.

Molecular coevolution of coagulation factor VIII and von Willebrand factor.

E. Gaucher, H. Spencer, C. Doering, 2021, Blood advances.

Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII.

H. Spencer, C. Doering, B. Gangadharan, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII

C. Bishop, C. Langefeld, A. Atala, 2022, Frontiers in Immunology.

Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A

C. Rodman, A. Atala, G. Almeida-Porada, 2021, Frontiers in Cell and Developmental Biology.

Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII

H. Spencer, C. Doering, Athena L. Russell, 2021, Molecular therapy. Methods & clinical development.

Target-Cell-Directed Bioengineering Approaches for Gene Therapy of Hemophilia A

H. Spencer, C. Doering, P. Zakas, 2018, Molecular therapy. Methods & clinical development.

Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens.

H. Spencer, C. Doering, B. Gangadharan, 2007, Blood.

Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines

H. Spencer, C. Doering, R. Moot, 2018, Oncoimmunology.

Non-signaling Chimeric Antigen Receptors Enhance Antigen-Directed Killing by gamma delta T Cells in Contrast to alpha beta T Cells

S. Becker, H. Spencer, C. Doering, 2022 .

Human serum albumin and chromatin condensation rescue ex vivo expanded γδ T cells from the effects of cryopreservation.

H. Spencer, C. Doering, R. E. Burnham, 2021, Cryobiology.

Factor VIII expression in azoxymethane-induced murine fulminant hepatic failure.

C. Doering, P. Lollar, C. Josephson, 2002, Blood.

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model

H. Spencer, C. Doering, K. Sutton, 2019, Oncoimmunology.

Platelet clearance via shear-induced unfolding of a membrane mechanoreceptor

David S. Paul, Yan Xu, Renhao Li, 2016, Nature Communications.

Decreased factor VIII levels during acetaminophen-induced murine fulminant hepatic failure.

C. Doering, P. Lollar, E. Parker, 2003, Blood.

Lentiviral gene therapy for familial hemophagocytic lymphohistiocytosis type 3, caused by UNC13D genetic defects.

H. Spencer, C. Doering, J. Shields, 2020, Human gene therapy.

Bioengineering and serum free expansion of blood-derived γδ T cells.

A. Dasgupta, H. Spencer, C. Doering, 2016, Cytotherapy.

regimens porcine factor VIII transgene and nonmyeloablative conditioning Hematopoietic stem-cell gene therapy of hemophilia A incorporating a

C. Doering, B. Gangadharan, K. Chiang, 2013 .

F5‐Atlanta: A novel mutation in F5 associated with enhanced East Texas splicing and FV‐short production

A. Rivera, C. Kempton, C. Doering, 2021, Journal of thrombosis and haemostasis : JTH.

Thrombopoietin-based CAR-T cells demonstrate in vitro and in vivo cytotoxicity to MPL positive acute myelogenous leukemia and hematopoietic stem cells

H. Spencer, C. Doering, Allison M. Lytle, 2021, Gene Therapy.

African-Americans Express Multiple Haplotypic Forms of the Wildtype Factor VIII (FVIII) Protein: A Possible Role for Pharmacogenetics in FVIII Inhibitor Development?.

L. Almasy, J. Soria, C. Doering, 2004 .

Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials

H. Spencer, C. Doering, K. Goldsmith, 2022, Oncoimmunology.

Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors

H. Spencer, C. Doering, R. Moot, 2016, Molecular therapy oncolytics.

Unaccompanied mechanosensory domain mediates low expression of glycoprotein Ibα: implications for Bernard‐Soulier syndrome

X. Mo, Renhao Li, C. Doering, 2019, Journal of thrombosis and haemostasis : JTH.

Controlled overexpression of BCKD kinase expression: metabolic engineering applied to BCAA metabolism in a mammalian system.

C. Doering, D. Danner, I. R. Williams, 2000, Metabolic engineering.

Murine branched chain alpha-ketoacid dehydrogenase kinase; cDNA cloning, tissue distribution, and temporal expression during embryonic development.

C. Doering, D. Danner, W. Spangler, 1998, Gene.

Microfluidic Transduction Harnesses Mass Transport Principles to Enhance Gene Transfer Efficiency

D. R. Myers, W. Lam, H. Spencer, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Insulin increases branched-chain α-ketoacid dehydrogenase kinase expression in Clone 9 rat cells

A. Kasinski, C. Doering, M. Nellis, 2002 .

Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction

Shannon L Meeks, Eric A Gaucher, E. Gaucher, 2016, Nature Biotechnology.

SAXS analysis of intrinsic tenase complex bound to lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa

H. Spencer, C. Doering, P. Lollar, 2021, bioRxiv.

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers

S. Becker, H. Spencer, C. Doering, 2023, Molecular therapy oncolytics.

Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

H. Spencer, C. Doering, Sunil S. Raikar, 2020, Cytotherapy.

Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma

Ronghu Wu, H. Spencer, C. Doering, 2023, Cell reports. Medicine.

Regulatory Framework for Academic Investigator-Sponsored Investigational New Drug Development of Cell and Gene Therapies in the USA

A. Dasgupta, Kristen Herzegh, H. Spencer, 2021, Current Stem Cell Reports.

In Utero Transplantation of FVIII-Expressing Human Placental Cells Upregulates Gene Pathways Associated with Immune Tolerance, Altering the Response to Postnatal FVIII Infusion

A. Atala, C. Porada, H. Spencer, 2021, Blood.

Engineering CD5-Targeted Chimeric Antigen Receptors and Edited T Cells for the Treatment of T-Cell Leukemia

H. Spencer, C. Doering, R. Moot, 2017 .

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity

A. Atala, D. Schwahn, G. Almeida-Porada, 2023, Nature communications.

Structure of coagulation factor VIII bound to a patient-derived anti–C1 domain antibody inhibitor

O. Davulcu, C. Doering, P. Lollar, 2023, Blood.

Structure of Blood Coagulation Factor VIII in Complex with an Anti-C1 Domain Pathogenic Antibody Inhibitor.

H. Spencer, C. Doering, P. Lollar, 2021, Blood.

Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia

J. Medin, H. Spencer, C. Doering, 2023, Frontiers in immunology.

Enhancing the effectiveness of y8 T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers

C. Doering, Harrison C. Brown, Sunil S. Raikar, 2022 .